HealthEquity, Inc. (NASDAQ:HQY) Receives $103.83 Average PT from Brokerages

HealthEquity, Inc. (NASDAQ:HQY) has received a consensus rating of “Buy” from the twelve brokerages that are covering the firm, MarketBeat.com reports. Twelve investment analysts have rated the stock with a buy rating. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $103.83.

Several brokerages have weighed in on HQY. JMP Securities reaffirmed a “market outperform” rating and set a $105.00 target price on shares of HealthEquity in a research note on Wednesday, September 4th. Deutsche Bank Aktiengesellschaft boosted their price target on shares of HealthEquity from $102.00 to $103.00 and gave the company a “buy” rating in a report on Wednesday, September 4th. Barrington Research restated an “outperform” rating and set a $105.00 price target on shares of HealthEquity in a report on Friday, September 20th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $92.00 target price on shares of HealthEquity in a research report on Wednesday, September 4th. Finally, Bank of America cut their price target on shares of HealthEquity from $105.00 to $100.00 and set a “buy” rating on the stock in a report on Wednesday, September 4th.

HealthEquity Price Performance

HealthEquity stock opened at $87.57 on Tuesday. HealthEquity has a one year low of $61.81 and a one year high of $89.23. The company has a debt-to-equity ratio of 0.51, a quick ratio of 4.10 and a current ratio of 4.10. The company has a market cap of $7.62 billion, a P/E ratio of 95.18, a price-to-earnings-growth ratio of 1.31 and a beta of 0.52. The business has a fifty day moving average of $80.05 and a two-hundred day moving average of $79.68.

HealthEquity (NASDAQ:HQY) last announced its quarterly earnings data on Tuesday, September 3rd. The company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.50 by $0.16. The business had revenue of $299.93 million for the quarter, compared to analyst estimates of $284.48 million. HealthEquity had a net margin of 9.61% and a return on equity of 9.01%. As a group, analysts predict that HealthEquity will post 2.27 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Frank Corvino sold 1,247 shares of HealthEquity stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $80.26, for a total transaction of $100,084.22. Following the sale, the director now directly owns 4,823 shares in the company, valued at $387,093.98. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, Director Frank Corvino sold 1,247 shares of the stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $80.26, for a total value of $100,084.22. Following the transaction, the director now owns 4,823 shares of the company’s stock, valued at $387,093.98. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Robert W. Selander sold 8,250 shares of the firm’s stock in a transaction that occurred on Wednesday, October 9th. The stock was sold at an average price of $82.98, for a total transaction of $684,585.00. Following the completion of the transaction, the director now owns 54,719 shares in the company, valued at $4,540,582.62. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 2.20% of the stock is owned by company insiders.

Hedge Funds Weigh In On HealthEquity

Institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. grew its stake in HealthEquity by 1.7% in the first quarter. Vanguard Group Inc. now owns 8,768,632 shares of the company’s stock valued at $715,783,000 after purchasing an additional 149,133 shares during the last quarter. Wasatch Advisors LP increased its holdings in HealthEquity by 8.3% in the 1st quarter. Wasatch Advisors LP now owns 7,409,080 shares of the company’s stock worth $604,803,000 after acquiring an additional 569,249 shares in the last quarter. Motley Fool Asset Management LLC lifted its stake in HealthEquity by 3,001.0% in the 1st quarter. Motley Fool Asset Management LLC now owns 3,762,064 shares of the company’s stock valued at $307,097,000 after buying an additional 3,640,748 shares in the last quarter. Clearbridge Investments LLC lifted its position in shares of HealthEquity by 1.9% in the second quarter. Clearbridge Investments LLC now owns 2,377,204 shares of the company’s stock valued at $204,915,000 after acquiring an additional 43,491 shares in the last quarter. Finally, Mackenzie Financial Corp lifted its holdings in HealthEquity by 16.0% in the 2nd quarter. Mackenzie Financial Corp now owns 2,364,521 shares of the company’s stock valued at $203,822,000 after purchasing an additional 325,906 shares in the last quarter. 99.55% of the stock is owned by hedge funds and other institutional investors.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.